2089 Response to chemotherapy allows to identify mCRC patients most likely to benefit from maintenance immunotherapy: A post-hoc analysis from the IMPACT study. (September 2015) - Scheithauer, W.; Riera-Knorrenschild, J.; Kopp, H.G.; Mayer, F.; Kroening, H.; Nitsche, D.; Kuhlmann, J.; Ziebermayr, R.; Andel, J.; Arnold, D.; Zurlo, A.; Wittig, B.; et al.